The ambition at Isomorphic Labs is to develop a drug design engine that can continuously adapt and apply to new challenges across different diseases, fundamentally changing drug discovery.

Our sister company, Isomorphic Labs, is developing technologies around AlphaFold to design drug compounds that bind to specific parts of protein surfaces, which is crucial for understanding diseases.

Many team members at Isomorphic Labs come from non-traditional backgrounds, which allows for fresh perspectives and innovative problem-solving.

Partnerships with Eli Lilly and Novartis have allowed us to tackle challenging problems in drug design, leading to the discovery of new chemical matter.

There's a significant opportunity in generating in vivo data, which is currently limited, to better understand drug interactions in real biological systems, and we're seeing breakthroughs in data-generating technology in biology and chemistry that will significantly impact how we model these fields.

Notable Labs began by providing tumor screening services to pharmaceutical companies, generating revenue and data to support their drug development efforts.

At Notable Labs, we focus on personalized drug discovery for blood cancer by testing combinations of approved drugs on patients' actual cells.

Our internal drug design projects focus on immunology and oncology, and we've made significant progress using advanced models.

Synthetic data plays a crucial role in drug discovery, especially in chemistry, where we can use theoretical models to create scalable molecular simulations and enhance the information content of our datasets.